Trial Title:
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT ID:
NCT06203600
Condition:
Advanced Esophageal Adenocarcinoma
Advanced Gastric Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Esophageal Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Esophageal Adenocarcinoma
Unresectable Gastric Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Conditions: Official terms:
Adenocarcinoma
Stomach Neoplasms
Esophageal Neoplasms
Paclitaxel
Nivolumab
Albumin-Bound Paclitaxel
Ramucirumab
Antineoplastic Agents, Immunological
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Lexatumumab
Study type:
Interventional
Study phase:
Phase 2/Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo optional blood sample collection
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT scan
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Biological
Intervention name:
Nivolumab
Description:
Given IV
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Other name:
ABP 206
Other name:
BCD-263
Other name:
BMS 936558
Other name:
BMS-936558
Other name:
BMS936558
Other name:
CMAB819
Other name:
MDX 1106
Other name:
MDX-1106
Other name:
MDX1106
Other name:
NIVO
Other name:
Nivolumab Biosimilar ABP 206
Other name:
Nivolumab Biosimilar BCD-263
Other name:
Nivolumab Biosimilar CMAB819
Other name:
ONO 4538
Other name:
ONO-4538
Other name:
ONO4538
Other name:
Opdivo
Intervention type:
Drug
Intervention name:
Paclitaxel
Description:
Given IV
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Other name:
Anzatax
Other name:
Asotax
Other name:
Bristaxol
Other name:
Praxel
Other name:
Taxol
Other name:
Taxol Konzentrat
Intervention type:
Other
Intervention name:
Questionnaire Administration
Description:
Ancillary studies
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Intervention type:
Biological
Intervention name:
Ramucirumab
Description:
Given IV
Arm group label:
Arm 1 (nivolumab, ramucirumab, paclitaxel)
Arm group label:
Arm 2 (ramucirumab, paclitaxel)
Other name:
Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
Other name:
Cyramza
Other name:
IMC 1121B
Other name:
IMC-1121B
Other name:
IMC1121B
Other name:
LY 3009806
Other name:
LY-3009806
Other name:
LY3009806
Other name:
Monoclonal Antibody HGS-ETR2
Summary:
This phase II/III trial compares the addition of nivolumab to the usual treatment of
paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with
gastric or esophageal adenocarcinoma that may have spread from where it first started to
nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal
antibody is a type of protein that can bind to certain targets in the body, such as
molecules that cause the body to make an immune response (antigens). Immunotherapy with
monoclonal antibodies, such as nivolumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab
is a monoclonal antibody that may prevent the growth of new blood vessels that tumors
need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It
stops cancer cells from growing and dividing and may kill them. Adding nivolumab to
ramucirumab and paclitaxel may work better to treat patients with advanced stomach or
esophageal cancer.
Detailed description:
PRIMARY OBJECTIVES:
I. To assess whether progression-free survival (PFS) is sufficiently improved in
participants randomized to nivolumab + paclitaxel + ramucirumab compared to those
randomized to paclitaxel + ramucirumab to warrant a phase III study with overall survival
(OS) as the primary endpoint. (Phase II) II. To compare OS in participants randomized to
nivolumab + paclitaxel + ramucirumab versus those randomized to paclitaxel + ramucirumab.
(Phase III)
SECONDARY OBJECTIVES:
I. To compare PFS between those randomized to nivolumab + paclitaxel + ramucirumab versus
those randomized to paclitaxel + ramucirumab. (Phase III) II. To compare OS between
participants randomized to nivolumab + paclitaxel + ramucirumab compared to those
randomized to paclitaxel + ramucirumab in the event that the trial is completed before
the phase III portion.
III. To compare the overall response rate (ORR, including confirmed and unconfirmed,
complete, and partial response, according to Response Evaluation Criteria in Solid Tumors
[RECIST 1.1] criteria) between those randomized to nivolumab + paclitaxel + ramucirumab
compared to those randomized to paclitaxel + ramucirumab among participants with
measurable disease.
IV. To compare the overall disease control rate (DCR = ORR + stable disease) between
those randomized to nivolumab + paclitaxel + ramucirumab compared to those randomized to
paclitaxel + ramucirumab among participants with measurable disease.
V. To evaluate the safety and tolerability of each treatment regimen. VI. To compare
health-related quality of life (QOL) by treatment arm at 8 weeks after randomization,
measured using the Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) Trial
Outcome Index (TOI).
VII. To compare health-related QOL between treatment arms at 8 weeks after randomization
using the FACT-Ga total score.
VIII. To compare longitudinal changes in health-related QOL between treatment arms using
FACT-Ga TOI up to 24 weeks after randomization.
IX. To compare patient-reported symptoms using selected Patient-Reported Outcomes-Common
Terminology Criteria for Adverse Events (PRO-CTCAE) items including gastrointestinal as
well as constitutional symptoms of fatigue, anorexia, and weight loss between treatment
arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each
cycle, ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, and paclitaxel
IV over 60 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the
absence of disease progression or unacceptable toxicity. Patients undergo computed
tomography (CT) scan and magnetic resonance imaging (MRI) throughout the study. Patients
may also optionally undergo blood sample collection on study.
ARM 2: Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle
and paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every
28 days in the absence of disease progression or unacceptable toxicity. Patients undergo
CT scan and MRI throughout the study. Patients may also optionally undergo blood sample
collection on study.
After completion of study treatment, patients are followed up at 30, 60, 90 days and then
every 6 months for up to 3 years.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participants must have advanced or locally unresectable gastric, gastroesophageal
junction or esophageal adenocarcinoma
- Participants must have PD-L1 CPS (Combined Positive Score) ≥ 1. This test would have
been performed as part of standard of care (SOC) pathology testing, using tissue
obtained within two years prior to registration and collected prior to or after a
frontline regimen
- Participants must have a histologically confirmed diagnosis of microsatellite stable
(MSS) and HER2 negative gastric, gastroesophageal junction, or esophageal
adenocarcinoma
- Participants must have documented unresectable and/or metastatic disease on CT or
MRI imaging completed prior to registration. Imaging must have been completed within
28 days prior to registration for participants with measurable disease. CT scans or
MRIs used to assess non-measurable disease must have been completed within 42 days
prior to registration. All disease must be assessed and documented on the Baseline
Tumor Assessment Form
- Participants with treated brain metastases must have no evidence of progression on
the follow-up brain imaging after central nervous system (CNS)-directed therapy. All
treatment for brain metastases must have been completed at least 28 days prior to
registration
- Participants must have disease progression or intolerance to frontline standard of
care (SOC) chemotherapy plus either nivolumab, pembrolizumab or any other PD-1 or
PD-L1 inhibitor. Peri-operative chemotherapy plus nivolumab, pembrolizumab or any
other PD-1 or PD-L1 inhibitor will count as one line if disease progression occurs
while on the therapy or within 6 months of completing the chemotherapy plus
nivolumab or pembrolizumab or other PD-1/PD-L1 inhibitor cycle
- Participants must not have received more than one prior line of systemic therapy
- Participants must not have a condition requiring systemic treatment with either
corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive
medications within 14 days of registration. Inhaled or topical steroids and adrenal
replacement doses < 10 mg daily prednisone equivalents are permitted in the absence
of active autoimmune disease. Participants are permitted to use topical, ocular,
intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic
absorption). Physiologic replacement doses of systemic corticosteroids are
permitted, even if < 10 mg/day prednisone equivalents. A brief course of
corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of
non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by
contact allergen) is permitted, as long as there has been a washout period for
corticosteroids of ≥ 7 days prior to registration
- Participants must not have prior significant immunotherapy related adverse events
requiring permanent discontinuation of the immunotherapy agent including events like
pneumonitis, myocarditis, renal failure, Guillain barre syndrome, or myasthenia
gravis. Participants with endocrinopathy events leading or not to replacement
steroids, thyroid hormone, insulin, or cortisol are eligible
- Participants must not have received a live attenuated vaccination within 28 days
prior to registration
- Participants must not have had a major surgery within 28 days or subcutaneous venous
access device placement within 7 days prior registration
- Participants must have fully recovered from the effects of prior surgery in the
opinion of the treating investigator. Any participants with postoperative bleeding
complications or wound complications from a surgical procedure performed in the last
eight weeks should be excluded
- Participants must not have plans to undergo elective or planned major surgery during
the clinical trial
- Participants must not have active bleeding or prior history of gastrointestinal (GI)
perforation, fistula or significant GI bleeding (requiring transfusion, endoscopic
or surgical intervention) within 84 days prior to registration
- Participants must not be planning to receive any concurrent chemotherapy,
immunotherapy, investigational agents, biologic or hormonal therapy for cancer
treatment while receiving treatment on this study
- Participants must not have a history of a grade 3 or 4 allergic reaction attributed
to humanized or human monoclonal antibody therapy
- Participants must not have a history of grade 3 or 4 immunotherapy related
toxicities with the exception of hormonal abnormalities like thyroiditis or thyroid
derangements
- Participants must be ≥ 18 years old
- Participants must have Zubrod Performance Status of 0-2
- Participants must have a complete medical history and physical exam within 28 days
prior to registration
- Leukocytes ≥ 2 x 10^3/uL (within 28 days prior to registration)
- Absolute neutrophil count ≥ 1.2 x 10^3/uL (within 28 days prior to registration)
- Hemoglobin ≥ 9.0 g/dL (within 28 days prior to registration)
- Platelets ≥ 100 x 10^3/uL (within 28 days prior to registration)
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days
prior to registration) unless history of Gilbert's disease. Participants with
history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional
ULN (within 28 days prior to registration) (unless liver metastases are present, in
which case they must be ≤ 5 x ULN)
- Participants must have a creatinine ≤ 1.5 x the institutional ULN OR calculated
creatinine clearance ≥ 40 mL/min using the following Cockcroft-Gault Formula. This
specimen must have been drawn and processed within 28 days prior to registration
- Participants' urinary protein must be ≤ 1+ on dipstick or routine urinalysis (UA)
within 28 days of registration. Random analysis of urine protein with a normal value
is sufficient. If urine dipstick or routine analysis indicated proteinuria ≥ 2+,
then a 24-hour urine is to be collected and demonstrate < 1000 mg of protein in 24
hours to allow participation in the study
- Participants must have adequate cardiac function. Participants with known history or
current symptoms of cardiac disease, or history of treatment with cardiotoxic
agents, must have a clinical risk assessment of cardiac function using the New York
Heart Association Functional Classification. To be eligible for this trial,
participants must be class 2 or better
- Participants must have recovered to baseline or < grade 2 CTCAE version (v) 5.0 from
toxicities related to any prior treatments, unless AE(s) are clinically stable on
supportive therapy
- Participants must not have experienced arterial thromboembolic events, including but
not limited to myocardial infarction, transient ischemic attack, cerebrovascular
accident, or unstable angina, within 6 months prior to registration
- Participants must not have uncontrolled blood pressure within 28 days prior to
registration as determined by the treating investigator
- Participants with known human immunodeficiency virus (HIV)-infection must be on
effective anti-retroviral therapy at registration and have undetectable viral load
on the most recent test results obtained within 6 months prior to registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load while on suppressive therapy on the most recent test
results obtained within 6 months prior to registration, if indicated
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants currently being treated for HCV infection must have
undetectable HCV viral load on the most recent test results obtained within 6 months
prior to registration, if indicated
- Participants must not have a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) has the potential to interfere
with the safety or efficacy assessment of the investigational regimen
- Participants must not be pregnant or nursing (nursing includes breast milk fed to an
infant by any means, including from the breast, milk expressed by hand, or pumped).
Individuals who are of reproductive potential must have agreed to use an effective
contraceptive method with details provided as a part of the consent process. A
person who has had menses at any time in the preceding 12 consecutive months or who
has semen likely to contain sperm is considered to be of "reproductive potential."
In addition to routine contraceptive methods, "effective contraception" also
includes refraining from sexual activity that might result in pregnancy and surgery
intended to prevent pregnancy (or with a side-effect of pregnancy prevention)
including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion,
and vasectomy with testing showing no sperm in the semen
- Participants must not have a history of inflammatory bowel disease, (including
ulcerative colitis and Crohn's disease), symptomatic autoimmune disease (e.g.,
rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus
erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); CNS or motor
neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and
myasthenia gravis, multiple sclerosis). Note: Participants with Graves' disease will
be allowed
- Participants must not have a history of pneumonitis that has required oral or IV
steroids within the last 12 months prior to registration
- Participants must be offered the opportunity to participate in specimen banking.
With participant consent, specimens must be collected and submitted via the
Southwest Oncology Group (SWOG) Specimen Tracking System
- Participants who can complete patient reported outcomes (FACT-Ga and PRO-CTCAE)
questionnaires in English or Spanish must participate in the quality of life studies
- Participants must be informed of the investigational nature of this study and must
sign and give informed consent in accordance with institutional and federal
guidelines. For participants with impaired decision-making capabilities, legally
authorized representatives may sign and give informed consent on behalf of study
participants in accordance with applicable federal, local, and Central Institutional
Review Board (CIRB) regulations
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Arkansas for Medical Sciences
Address:
City:
Little Rock
Zip:
72205
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
501-686-8274
Investigator:
Last name:
Rangaswamy Govindarajan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Anaheim
Address:
City:
Anaheim
Zip:
92806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Baldwin Park
Address:
City:
Baldwin Park
Zip:
91706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Bellflower
Address:
City:
Bellflower
Zip:
90706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Fontana
Address:
City:
Fontana
Zip:
92335
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente South Bay
Address:
City:
Harbor City
Zip:
90710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Irvine
Address:
City:
Irvine
Zip:
92618
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Keck Medicine of USC Koreatown
Address:
City:
Los Angeles
Zip:
90020
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
213-388-0908
Investigator:
Last name:
Syma Iqbal
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente Los Angeles Medical Center
Address:
City:
Los Angeles
Zip:
90027
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Los Angeles General Medical Center
Address:
City:
Los Angeles
Zip:
90033
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
323-865-0451
Email:
uscnorrisinfo@med.usc.edu
Investigator:
Last name:
Syma Iqbal
Email:
Principal Investigator
Facility:
Name:
USC / Norris Comprehensive Cancer Center
Address:
City:
Los Angeles
Zip:
90033
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
323-865-0451
Investigator:
Last name:
Syma Iqbal
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente West Los Angeles
Address:
City:
Los Angeles
Zip:
90034
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
USC Norris Oncology/Hematology-Newport Beach
Address:
City:
Newport Beach
Zip:
92663
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
323-865-0451
Investigator:
Last name:
Syma Iqbal
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Ontario
Address:
City:
Ontario
Zip:
91761
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente - Panorama City
Address:
City:
Panorama City
Zip:
91402
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Riverside
Address:
City:
Riverside
Zip:
92505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-San Diego Zion
Address:
City:
San Diego
Zip:
92120
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-San Marcos
Address:
City:
San Marcos
Zip:
92078
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Woodland Hills
Address:
City:
Woodland Hills
Zip:
91367
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-398-3996
Email:
clinical.trials@kp.org
Investigator:
Last name:
Gary L. Buchschacher
Email:
Principal Investigator
Facility:
Name:
UCHealth Memorial Hospital Central
Address:
City:
Colorado Springs
Zip:
80909
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
719-365-2406
Investigator:
Last name:
Robert J. Hoyer
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital North
Address:
City:
Colorado Springs
Zip:
80920
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
719-364-6700
Investigator:
Last name:
Robert J. Hoyer
Email:
Principal Investigator
Facility:
Name:
Beebe South Coastal Health Campus
Address:
City:
Millville
Zip:
19967
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Helen F Graham Cancer Center
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Medical Oncology Hematology Consultants PA
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Beebe Health Campus
Address:
City:
Rehoboth Beach
Zip:
19971
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
MedStar Georgetown University Hospital
Address:
City:
Washington
Zip:
20007
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
202-444-2223
Investigator:
Last name:
Reetu Mukherji
Email:
Principal Investigator
Facility:
Name:
AdventHealth Orlando
Address:
City:
Orlando
Zip:
32803
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
407-303-2090
Email:
FH.Cancer.Research@flhosp.org
Investigator:
Last name:
Mohamedtaki A. Tejani
Email:
Principal Investigator
Facility:
Name:
Hawaii Cancer Care - Westridge
Address:
City:
'Aiea
Zip:
96701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-539-2273
Email:
info@hawaiicancercare.com
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
The Queen's Medical Center - West Oahu
Address:
City:
'Ewa Beach
Zip:
96706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
rohta@queens.org
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
Hawaii Cancer Care Inc - Waterfront Plaza
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-524-6115
Email:
i.webster@hawaiicancercare.com
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
Queen's Cancer Cenrer - POB I
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-532-0315
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
Queen's Medical Center
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-545-8548
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
Queen's Cancer Center - Kuakini
Address:
City:
Honolulu
Zip:
96817
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-531-8521
Investigator:
Last name:
Elizabeth S. Nakasone
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Rush - Copley Medical Center
Address:
City:
Aurora
Zip:
60504
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-978-6212
Email:
Cancer.Research@rushcopley.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-285-7800
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Mercyhealth Javon Bea Hospital - Rockton
Address:
City:
Rockford
Zip:
61103
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-396-3729
Email:
oncologyclinicaltrials@mhemail.org
Investigator:
Last name:
Gregory M. Richards
Email:
Principal Investigator
Facility:
Name:
UW Health Carbone Cancer Center Rockford
Address:
City:
Rockford
Zip:
61114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
779-696-9378
Email:
lkline@uwhealth.org
Investigator:
Last name:
Fahrettin Covut
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital East
Address:
City:
Shiloh
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-747-9912
Email:
dschwab@wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Saint Anthony Regional Hospital
Address:
City:
Carroll
Zip:
51401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-689-7658
Email:
sbenson@iora.org
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Cedar Rapids
Zip:
52403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
319-365-4673
Investigator:
Last name:
Deborah W. Wilbur
Email:
Principal Investigator
Facility:
Name:
Oncology Associates at Mercy Medical Center
Address:
City:
Cedar Rapids
Zip:
52403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
319-363-2690
Investigator:
Last name:
Deborah W. Wilbur
Email:
Principal Investigator
Facility:
Name:
Iowa Methodist Medical Center
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-6727
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Broadlawns Medical Center
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2200
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Trinity Regional Medical Center
Address:
City:
Fort Dodge
Zip:
50501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-574-8302
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Saint Joseph Hospital East
Address:
City:
Lexington
Zip:
40509
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
720-874-1881
Email:
ResearchInstituteInquiries@CommonSpirit.org
Investigator:
Last name:
Shahzad Siddique
Email:
Principal Investigator
Facility:
Name:
Ochsner Medical Center Jefferson
Address:
City:
New Orleans
Zip:
70121
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
504-842-8084
Email:
Elisemarie.curry@ochsner.org
Investigator:
Last name:
Jonathan D. Mizrahi
Email:
Principal Investigator
Facility:
Name:
UPMC Western Maryland
Address:
City:
Cumberland
Zip:
21502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
240-964-1400
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Health Providence Novi Hospital
Address:
City:
Novi
Zip:
48374
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-849-5332
Email:
kfife3@hfhs.org
Investigator:
Last name:
Adam M. Forman
Email:
Principal Investigator
Facility:
Name:
Henry Ford Health Providence Southfield Hospital
Address:
City:
Southfield
Zip:
48075
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-849-5332
Email:
kfife3@hfhs.org
Investigator:
Last name:
Adam M. Forman
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Bellevue
Address:
City:
Bellevue
Zip:
68123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Laura L. Tenner
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Village Pointe
Address:
City:
Omaha
Zip:
68118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-5600
Investigator:
Last name:
Laura L. Tenner
Email:
Principal Investigator
Facility:
Name:
University of Nebraska Medical Center
Address:
City:
Omaha
Zip:
68198
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Laura L. Tenner
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Roswell Park Cancer Institute
Address:
City:
Buffalo
Zip:
14263
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-767-9355
Email:
askroswell@roswellpark.org
Investigator:
Last name:
Sarbajit Mukherjee
Email:
Principal Investigator
Facility:
Name:
Glens Falls Hospital
Address:
City:
Glens Falls
Zip:
12801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
518-926-6700
Investigator:
Last name:
Charles Yun
Email:
Principal Investigator
Facility:
Name:
University of Rochester
Address:
City:
Rochester
Zip:
14642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
585-275-5830
Investigator:
Last name:
Paul M. Barr
Email:
Principal Investigator
Facility:
Name:
Cone Health Cancer Center at Asheboro
Address:
City:
Asheboro
Zip:
27203
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Randolph Health Cancer Center
Address:
City:
Asheboro
Zip:
27203
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Email:
stacey.phelps@conehealth.com
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Cone Health Cancer Center at Alamance Regional
Address:
City:
Burlington
Zip:
27215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Email:
stacey.phelps@conehealth.com
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Cone Health Cancer Center
Address:
City:
Greensboro
Zip:
27403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Email:
stacey.phelps@conehealth.com
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Cone Health Cancer Center at Drawbridge Parkway
Address:
City:
Greensboro
Zip:
27410
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Email:
stacey.phelps@conehealth.com
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Annie Penn Memorial Hospital
Address:
City:
Reidsville
Zip:
27320
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
336-832-0836
Email:
stacey.phelps@conehealth.com
Investigator:
Last name:
Vinay K. Gudena
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital South
Address:
City:
Centerville
Zip:
45459
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Premier Blood and Cancer Center
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-276-8320
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital North
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Atrium Medical Center-Middletown Regional Hospital
Address:
City:
Franklin
Zip:
45005-1066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Cancer Care and Infusion
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-569-7515
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Upper Valley Medical Center
Address:
City:
Troy
Zip:
45373
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Hassan Hatoum
Email:
Principal Investigator
Facility:
Name:
Providence Newberg Medical Center
Address:
City:
Newberg
Zip:
97132
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Willamette Falls Medical Center
Address:
City:
Oregon City
Zip:
97045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Oregon Health and Science University
Address:
City:
Portland
Zip:
97239
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-494-1080
Email:
trials@ohsu.edu
Investigator:
Last name:
Emerson Y. Chen
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center Erie
Address:
City:
Erie
Zip:
16505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Address:
City:
Harrisburg
Zip:
17109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
717-724-6765
Email:
klitchfield@PINNACLEHEALTH.org
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Address:
City:
Mechanicsburg
Zip:
17050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC-Saint Margaret
Address:
City:
Pittsburgh
Zip:
15215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-784-4900
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
University of Pittsburgh Cancer Institute (UPCI)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-647-8073
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC-Passavant Hospital
Address:
City:
Pittsburgh
Zip:
15237
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-367-6454
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
Ralph H Johnson VA Medical Center
Address:
City:
Charleston
Zip:
29401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
843-789-7020
Email:
ashley.salvo@va.gov
Investigator:
Last name:
Oleksandra Lupak
Email:
Principal Investigator
Facility:
Name:
Sanford Cancer Center Oncology Clinic
Address:
City:
Sioux Falls
Zip:
57104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicTrialsSF@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford USD Medical Center - Sioux Falls
Address:
City:
Sioux Falls
Zip:
57117-5134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicalTrialsSF@SanfordHealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
713-798-1354
Email:
burton@bcm.edu
Investigator:
Last name:
Karen Riggins
Email:
Principal Investigator
Facility:
Name:
Ben Taub General Hospital
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
713-873-2000
Investigator:
Last name:
Karen Riggins
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center Green Bay
Address:
City:
Green Bay
Zip:
54301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Saint Mary's
Address:
City:
Green Bay
Zip:
54303
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Address:
City:
Madison
Zip:
53718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Facility:
Name:
ProHealth D N Greenwald Center
Address:
City:
Mukwonago
Zip:
53149
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
research.institute@phci.org
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
ProHealth Oconomowoc Memorial Hospital
Address:
City:
Oconomowoc
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-7878
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Oconto Falls
Address:
City:
Oconto Falls
Zip:
54154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Address:
City:
Sturgeon Bay
Zip:
54235-1495
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
ProHealth Waukesha Memorial Hospital
Address:
City:
Waukesha
Zip:
53188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-7632
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
UW Cancer Center at ProHealth Care
Address:
City:
Waukesha
Zip:
53188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-5539
Email:
Chanda.miller@phci.org
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Start date:
June 24, 2024
Completion date:
October 31, 2027
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06203600
